UNDERLYING MECHANISMS OF SCHISTOSOME/SNAIL COMPATIBILITY
Project Number5R01AI016137-12
Former Number2R22AI016137-10A1
Contact PI/Project LeaderBAYNE, CHRISTOPHER JEFFREY
Awardee OrganizationOREGON STATE UNIVERSITY
Description
Abstract Text
On account of the considerable burden placed on human populations by
Schistosoma mansoni in schistosome-endemic areas, an understanding of the
basic mechanisms responsible for transmission of these human parasites via
their intermediate molluscan hosts is desirable. This research seeks to
understand how it is that a miracidium larva is able to penetrate a snail
and transform into a sporocyst without eliciting aggressive defensive
responses. Since individual snails (Biomphalaria glabrata) may be
susceptible or resistant to individual S. mansoni, the cellular and
molecular bases for this variability are to be sought. At least some
components of this mollusc's internal defense system are subject to
modulation by trematode parasites and by stress. Therefore, following
treatments proven to modulate hemocyte activity, the influence of such
altered states will be evaluated in assays of snail resistance. Assays
include in vitro phagocytosis, cytoadherence and cell mediated
cytotoxicity, and in vivo resistance to S. mansoni. An hypothesis that the
compatibility of schistosome and snail is due in part to mimicry of
carbohydrate epitopes will be tested using polyclonal sera, with antigens
subjected to proteolytic degradation, and known carbohydrate epitopes used
as competing ligands. Substantively improved quantification of in vitro
cytotoxicity will allow us to determine whether resistant plasma
accelerates sporocyst killing. Another hypothesis implicating
lysosomally-derived, plasma enzymes in modulating resistance will be tested
both in vivo and in vitro using plasma from appropriately treated snails
and defined enzymes. A functional role will be sought for a 50 kD plasma
component found uniquely in strains of snail which are resistant to the PR1
strain of S. mansoni. Polyclonal antisera will be used in efforts to block
effector functions, and the affinity-purified plasma component will be
evaluated for its ability to facilitate recognition and/or cytotoxic
hemocyte effector functions. Finally, the relevance of a novel
alpha-macroglobulin-like protein in snail plasma to outcomes of snail -
schistosome encounters will be investigated.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
BiomphalariaSDS polyacrylamide gel electrophoresisSchistosoma mansonialternatives to animals in researchcell mediated cytotoxicitycellular immunitycellular pathologycommunicable disease transmissionendopeptidasesenzyme activityhamstershost organism interactionmembrane activitymicroorganism immunologymolecular pathologyphagocytosisproteolysisprotozoal antigenschistosomiasistissue /cell culturewestern blottings
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
053599908
UEI
MZ4DYXE1SL98
Project Start Date
30-September-1981
Project End Date
31-March-1996
Budget Start Date
01-April-1994
Budget End Date
31-March-1995
Project Funding Information for 1994
Total Funding
$215,951
Direct Costs
$154,251
Indirect Costs
$61,700
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Allergy and Infectious Diseases
$215,951
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI016137-12
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI016137-12
Patents
No Patents information available for 5R01AI016137-12
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI016137-12
Clinical Studies
No Clinical Studies information available for 5R01AI016137-12
News and More
Related News Releases
No news release information available for 5R01AI016137-12
History
No Historical information available for 5R01AI016137-12
Similar Projects
No Similar Projects information available for 5R01AI016137-12